|
Feb 11
|
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 4
|
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
|
|
Jan 30
|
7MM PD market to grow by $4.5bn between 2023 and 2033
|
|
Jan 7
|
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five years
|